Contains A Growth Factor Or Growth Regulator Patents (Class 435/405)
-
Patent number: 7892830Abstract: While culture medium and systems have been described that permit the culture and proliferation of human embryonic stem cells in feeder free and animal product free conditions, these conditions will not readily support cloning of an embryonic stem cell culture meaning, at least here, the initiation of a sub-culture using one or a very few originating cells. It has been found here that a class of small molecules that are inhibitors of kinase enzymes will increase the efficiency of cloning of stem cell cultures sufficiently to make such cloning practical in the defined medium and in other media as well.Type: GrantFiled: January 17, 2008Date of Patent: February 22, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Veit Bergendahl, James A. Thomson
-
Publication number: 20110038903Abstract: Apparatus and process to create, expand, and localize the population of stem cells in adult tissues by placing a foreign body either in omentum or in the subcutaneous tissue. The apparatus 1) traps the granulation fluid, cells a fluid rich in a myriad of growth factors, 2) mobilizes and concentrates free-floating stem cells in the granulation fluid, and 3) stimulates the growth of a new tissue around the apparatus, which provides another source of stem cells. Stem cells obtained by this process can be used as freshly isolated or after culturing, which can be used for wound healing, treating diseases, and regenerating organs in animals and humans. The granulation fluid could substitute the stem cells in many of their applications and offers the convenience of an injectable medicine for treating animal and human diseases.Type: ApplicationFiled: August 13, 2010Publication date: February 17, 2011Inventor: Ashok K. Singh
-
Publication number: 20110014691Abstract: The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.Type: ApplicationFiled: March 10, 2009Publication date: January 20, 2011Applicants: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DECARTES, UNIVERSITE PARIS DIDEROT PARIS 7, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Philippe Menasche, Michel Puceat, Jérôme Larghero, Guillaume Blin, David Nury, Sonia Stefanovic
-
Publication number: 20110008893Abstract: Disclosed are a medium for mammalian somatic cells with which mammalian somatic cells can be grown effectively when the mammalian somatic cells are cultured, while reducing the amount of serum to be added to the medium as much as possible or without adding serum thereto, and an additive to constitute the medium. By blending of a ligand for an endothelial cell differentiation gene (Edg) family receptor and a ligand for a serotonin receptor to a medium, somatic cells of mammals can be grown even in cases where the medium does not contain serum at all or contains only a small amount thereof.Type: ApplicationFiled: December 26, 2008Publication date: January 13, 2011Applicant: FUJIREBIO INC.Inventors: Itsuro Sugimura, Yoshiyuki Hotta, Harumi Yamaguma
-
Publication number: 20100316613Abstract: A cell culture medium and system are provided which eliminates or at least reduces the need for feeder cells. The cell culture medium comprises one or more factors that are normally secreted and/or produced by a feeder cell and a synthetic chimeric protein comprising IGF-I and a portion of vitronectin. The cell culture medium is particularly suitable for propagating human embryonic stem cells and keratinocytes. This invention also relates to compositions and methods which utilize the cells cultured in the cell culture medium of the invention.Type: ApplicationFiled: September 3, 2008Publication date: December 16, 2010Inventors: Zee Upton, David Leavesley, Sean Dennis Richards, Luke Bryant Cormack, Damien Harkin
-
Publication number: 20100311166Abstract: The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.Type: ApplicationFiled: January 18, 2007Publication date: December 9, 2010Applicant: ReNeuron, Inc.Inventors: Monica Florio, Aleksandar Francki, Wen-Ghih Tsang
-
Publication number: 20100297090Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.Type: ApplicationFiled: March 22, 2010Publication date: November 25, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: John P. Daley, Barbara M. Dadey, William C. Biddle, Michelle G. Wysocki
-
Publication number: 20100291045Abstract: Dynamic vibrational methods and devices for inducing differentiation of stem cells into vocal fold fibroblast-like cells or for generating vocal fold-like tissue from cultured cells. Also provided are matrices providing sustained release of growth factors, and bioreactors generating and delivering a high frequency vibration with in-plane shear stress to cultured cells.Type: ApplicationFiled: May 17, 2010Publication date: November 18, 2010Applicant: University of DelawareInventors: Xinqiao Jia, Mingde Jia, Amit K. Jha, Alexandra J.E. Farran, Zhixiang Tong
-
Publication number: 20100284976Abstract: The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention.Type: ApplicationFiled: March 28, 2007Publication date: November 11, 2010Applicant: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Dolores J. Schendel, Anke Zobywalski, Iris Bigalke
-
Publication number: 20100267141Abstract: The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.Type: ApplicationFiled: April 2, 2010Publication date: October 21, 2010Applicant: THE SCRIPPS RESEARCH INSTITUTEInventors: Yan Shi, Caroline Desponts, Tongxiang Lin, Wenlin Li, Saiyong Zhu, Sheng Ding
-
Publication number: 20100226898Abstract: Embodiments herein relate to compositions and methods for engraftment of and increasing survival of muscle cells in a subject in need thereof. In certain embodiments, compositions including myofibers and/or satellite stem cells may be administered to a subject. Other embodiments relate to compositions and methods for introducing one or more compounds to a subject using cell compositions disclosed herein. Still other embodiments relate to uses of these compositions in kits for portable applications and methods.Type: ApplicationFiled: April 11, 2008Publication date: September 9, 2010Inventors: Bradley Bruce Olwin, John K. Hall, Kathleen Kelly Tanaka
-
Publication number: 20100227401Abstract: Disclosed herein are media and processes for the ex vivo production of megakaryocytes from human CD34+ cells, in which human CD34+ cells, either being freshly isolated from a newborn's cord blood or having been subcultured in an expansion medium after isolation from a newborn's cord blood, are subjected to cultivation in a cultivating medium consisting essentially of a basal medium, a serum substitute and a cytokine cocktail, wherein the serum substitute consists of human serum albumin, insulin, and transferrin; and the cytokine cocktail consists of thrombopoietin (TPO), stem cell factor (SCF), Flt-3 ligand (FL), interleukin-3 (IL-3), IL-6, IL-9, and granulocyte-macrophage colony-stimulating factor (GM-CSF).Type: ApplicationFiled: April 5, 2010Publication date: September 9, 2010Applicant: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTEInventors: Chao-Ling YAO, Te-Wei CHEN, Shiaw-Min HWANG
-
Publication number: 20100189700Abstract: The present invention relates to a culture including a growth medium and a combination of cytokines consisting of i) interleukin-6 (IL6); ii) flt3-ligand (FLT3); iii) stem cell factor (SCF) and iv) thrombopoi-etin (TPO); the use of the culture for expanding. ex vivo stem cells and/or parental cells and cells differentiated therefrom, and the use of said cells obtainable from said expansion.Type: ApplicationFiled: July 9, 2008Publication date: July 29, 2010Applicant: Fondazione IRCCS Ca' Granda-Ospedale Maggiore PoliclinicoInventors: Lorenza Lazzari, Tiziana Montemurro, Rosaria Giordano, Paolo Rebulla, Girolamo Sirchia
-
Publication number: 20100184223Abstract: The present invention relates to a biomaterial for cell or tissue culture, based on a polymeric carrier, which contains at least one crosslinkable hydrophilic polymer. The polymer is functionalized with groups that are selected from maleimide, vinylsulfonic, acrylate, alkyl halide, azirine, pyridyl, thionitrobenzene acid groups, or arylating groups. The invention relates further to a method of production of said biomaterial, and the use of particular functionalizing groups for the production of a biomaterial for the cultivation of tissue and/or cells. The biomaterial can have biofactors that exert a particular action on cells.Type: ApplicationFiled: January 11, 2010Publication date: July 22, 2010Inventor: Helmut Wurst
-
Patent number: 7754486Abstract: A culture medium named MV06 enabling growth in vitro of both endothelial progenitor and myocardiac progenitor cells, composed of: Iscove's Modified Dubellco's Medium, Fetal calf serum, Horse serum, L-Glutamin (200 mM (100×)) Penicillin (10000 u/mL)/Streptomycin (1000 ?g/mL), Hu-R Bone Morphogenetic Protein 2 (BMP-2), Hu-R Fibroblast Growth Factor 2 (FGF2), and Hu-R Vascular Endothelial Growth Factor (VEGF).Type: GrantFiled: December 26, 2006Date of Patent: July 13, 2010Assignee: Institut de Recherche en Hematologie et TransplantationInventor: Stéphanie Pasquet-Vallejo
-
Publication number: 20100173409Abstract: A composition and method for in vitro fertilization is provided which uses culture media comprising elevated concentrations of lipoic acid. More specifically, the invention provides culture media for developmental cells having a lipoic acid concentration of 5 ?M to 40 ?M. Culture media that include lipoic acid at concentrations within the identified range are able to provide blastocysts with increased survival, increased cell numbers, increased inner cell masses and/or increased percentage of the total mass made up by the inner cell compared to blastocysts cultured in a control medium.Type: ApplicationFiled: April 10, 2008Publication date: July 8, 2010Applicant: VITROLIFE SWEDEN ABInventors: David K. Gardner, Mark G. Larman, Donald Linck
-
Publication number: 20100130544Abstract: The invention refers to the in vitro and in vivo use of parasympatholytic substances, preferably scopolamine, to potentiate and accelerate the differentiation of stem cells into cells with a tissue-specific phenotype, and the process and compositions related thereto.Type: ApplicationFiled: February 28, 2007Publication date: May 27, 2010Applicant: UNIVERSITA' DEGLI STUDI DI TORINOInventors: Antonio Ponzetto, Luisa Gennero, Maria Augusta Roos, Gian piero Pescarmona, Tetyana Denysenko, Paolo Di Nardo, Roberto Sangiorgio
-
Publication number: 20100129907Abstract: A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.Type: ApplicationFiled: January 28, 2010Publication date: May 27, 2010Applicant: Technion Research & Development Foundation Ltd.Inventors: Michal AMIT, Joseph Itskovitz-Eldor
-
Patent number: 7723105Abstract: The invention relates to a conditioned cell culture medium and a corresponding method to obtain it. The invention also refers to methods of using this cellconditioned medium for the maintenance, proliferation and differentiation of mammalian cells. The culture medium produced in accordance with the present invention is conditioned by the cell secretion activity of murine cells, in particular, those differentiated and immortalized transgenic hepatocytes, named MMH (Met Murine Hepatocyte). These media are employed in in vitro cell culture systems to induce maintenance, proliferation and differentiation of mammalian cells. The cells named MMH are differentiated non transformed murine hepatocytes that produce important biological molecules (e.g cytokines and growth factors) and, in accordance with the present invention, they are used in in vitro cell culture systems for the maintenance, proliferation and differentiation of mammalian cells.Type: GrantFiled: August 10, 2004Date of Patent: May 25, 2010Assignee: Instituto Nazionale per le MalattieInventors: Veronica Bordoni, Tonino Alonzi, Marco Tripodi
-
Patent number: 7723106Abstract: A stroma-free, serum-free, and chemically defined medium and a method for mononuclear cell expansion ex vivo using the same. An exemplary medium includes a basal medium, a serum substitute, and a cytokine formula.Type: GrantFiled: July 29, 2005Date of Patent: May 25, 2010Assignee: Food Industry Research & Development InstituteInventors: Shiaw-Min Hwang, Chao-Ling Yao, Tzu-Bou Hsieh, I-Ming Chu
-
Publication number: 20100105132Abstract: The present invention provides a process of isolation, proliferation and/or maintenance of mesenchymal stem cells (MSCs). The invention further provides a culture medium for proliferation and/or maintenance of human mesenchymal stem cells in xeno-free conditions. The culture medium provided in the present invention proliferates and/or maintains mesenchymal stem cell expansion while maintaining a multipotent phenotype.Type: ApplicationFiled: October 20, 2009Publication date: April 29, 2010Applicant: Stempeutics Research Private LimitedInventors: Satish Mahadeorao Totey, Kumar Uday Kolkundkar, Rakhi Pal, Madhuri Hanwate
-
Publication number: 20100075416Abstract: Disclosed is a growth factor supplement for stem cell culture media, stem cell culture media supplemented with the growth factor supplement, and methods for growing and maintaining stem cells in culture. The invention particularly relates to human stem cells, more particularly human embryonic stem cells, neonatal stem cells, adult stem cells, and IPS cells.Type: ApplicationFiled: December 23, 2008Publication date: March 25, 2010Applicant: SHILOH LABORATORIES, INC.Inventor: Thomas Primiano
-
Publication number: 20100075905Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: November 30, 2009Publication date: March 25, 2010Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20100068805Abstract: The present disclosure provides novel culture system and methods for culturing and propagating hESCs in a substantially undifferentiated state for several passages. The ability to grow such cells without differentiation has important applications for therapeutic uses of ES cells for treating human disorders using tissue transplantation and/or gene therapy techniques. In particular, the disclosure further relates to conditioned medium obtained from human germ lineage derived feeder cells (GLDF). The hESC lines are derived, cultured and propagated in substantially undifferentiated state using the conditioned media from GLDF cells of the disclosure. In particular, the disclosure relates to the xeno-free derivation, culture and propagation of hESCs using conditioned medium of GLDF cells obtained thereof.Type: ApplicationFiled: June 19, 2009Publication date: March 18, 2010Applicant: Stempeutics Research Private LimitedInventors: Satish Totey, Kumar Uday Kulkarni, Shobhit Saxena
-
Publication number: 20100015710Abstract: Compositions and methods for isolating and expanding human mesenchymal stem/progenitor cells through multiple passages in defined serum-free environments are provided. The culture media compositions includes a basal medium supplemented with a nutrient mixture such as Ham's F12 nutrient mixture, glutamine, buffer solutions such as sodium bicarbonate and hepes, serum albumin, a lipid mixture, insulin, transferrin, putrescine, progesterone, fetuin, hydrocortisone, ascorbic acid or its analogues such as ascorbic acid-2-phosphate, fibroblast growth factor and transforming growth factor ?, and are free of serum or other undefined serum substitutes such as platelet lysate. Methods employing these compositions and protein-coated surfaces for the isolation of mesenchymal stem/progenitor cells from human bone marrow and other tissues such as adipose tissue are also provided.Type: ApplicationFiled: April 27, 2009Publication date: January 21, 2010Inventors: Sunghoon Jung, Arindom Sen, Leo A. Behie
-
Publication number: 20100015713Abstract: The present invention comprises the production of components of cell culture media produced from plant cells and cell culture media containing the same. Heterologous DNA comprising genes encoding the desired component are introduced into plant cells, especially rice, which then produce the desired component. The component can be isolated from the plant cell and combined with other components to form the required cell culture medium.Type: ApplicationFiled: June 27, 2006Publication date: January 21, 2010Inventors: Scott Deeter, Joseph E. Schmidt, Kenneth J. Mabery, Delia R. Bethell, Ning Huang, Steve Clyde Pettit
-
Patent number: 7645609Abstract: The invention provides media and methods for culturing mammalian cells whereby the sialylation of a protein produced by the cells is increased. The medium can contain N-acetylmannosamine and, optionally, galactose. The medium may also comprise fructose and mannose. Alternatively, the medium can contain galactose and fructose and, optionally, can also comprise mannose and/or N-acetylmannosamine. The methods can be practiced along with other methods for culturing cells so as to increase the quantity or quality of a protein produced by the cells, including culturing the cells at a temperature below 37° C.Type: GrantFiled: July 15, 2003Date of Patent: January 12, 2010Assignee: Immunex CorporationInventor: Brian D. Follstad
-
Publication number: 20090304658Abstract: The present application aims at providing a treatment method effective for various cancers, immune deficiency diseases and infections, and a method of proliferating/activating cells associated therewith, which can be performed at such low costs that the methods can be applicable to nonhuman animals. A method of proliferating/activating cells of the present application comprises steps of, during the cell culture, supplementing a plant lectin (such as concanavalin A) and a growth factor having interleukin-2-like activity to the culture medium. Accordingly, the present method can proliferate/activate, on a preferential basis, a?-type T cells associated with cell-mediated immunity for cancers, immunodeficiency diseases and infectious diseases.Type: ApplicationFiled: August 1, 2007Publication date: December 10, 2009Inventors: Shinobu Watarai, Shigeru Nishikawa
-
Publication number: 20090280097Abstract: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.Type: ApplicationFiled: July 20, 2009Publication date: November 12, 2009Applicant: Celavie Biosciences, LLCInventor: Oleg V. Kopyov
-
Publication number: 20090275128Abstract: Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if high levels of fibroblast growth factor, gamma amino butyric acid, pipecholic acid, lithium and transforming growth factor beta are added to the medium in which the stem cells are cultured, the stem cells will remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium.Type: ApplicationFiled: September 12, 2008Publication date: November 5, 2009Inventors: James A. Thomson, Tenneille Ludwig
-
Publication number: 20090269848Abstract: Disclosed is an agent for improving at least one activity selected from the group consisting of the growth activity, adhesion activity and extension activity of mesenchymal stem cells, which comprises laminin-5 as an active ingredient. A method of culturing mesenchymal stem cells; a method of isolating mesenchymal stem cells; and a medium, vessel or sheet for use in culturing mesenchymal stem cells are also provided.Type: ApplicationFiled: August 17, 2006Publication date: October 29, 2009Inventors: Kaoru Miyazaki, Junko Hashimoto, Yoshinobu Kariya
-
Publication number: 20090238800Abstract: The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue.Type: ApplicationFiled: February 15, 2007Publication date: September 24, 2009Applicant: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.Inventors: Kameran Lashkari, Marie Shatos, Tat Fong Ng
-
Publication number: 20090233363Abstract: The invention relates to the production of adult dedifferentiated, programmable stem cells from human monocytes by cultivation of monocytes in a culture medium which contains M-CSF and IL-3. The invention further relates to pharmaceutical preparations, which contain the dedifferentiated, programmable stem cells and the use of these stem cells for the production of target cells and target tissue.Type: ApplicationFiled: May 28, 2009Publication date: September 17, 2009Inventors: Bernd Karl Friedrich Kremer, Fred Fandrich, Maren nee Schulze Ruhnke
-
Publication number: 20090233355Abstract: The present invention relates to an oocyte and/or embryo culture medium. The medium includes 0.0003 to 750 ng/ml IGF-II, or a variant or analogue thereof, and further includes either or both of 0.01 to 50 ?g/ml plasminogen, or a variant or analogue thereof, and 0.01 to 50 ?g/ml urokinase plasminogen activator, or a variant or analogue thereof.Type: ApplicationFiled: July 27, 2006Publication date: September 17, 2009Inventor: Claire Trelfold Roberts
-
Patent number: 7585673Abstract: A novel member of the heregulin superfamily has been identified which is designated “?-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. ?-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of ?-HRG nucleic acid for the recombinant production of ?-HRG). ?-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described.Type: GrantFiled: July 1, 2005Date of Patent: September 8, 2009Assignee: Genentech, Inc.Inventors: Gabriele Maria Schaefer, Mark Sliwkowski
-
Publication number: 20090202498Abstract: The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as SB203580 and protein growth factors of the FGF, IGF and BMP families such as but not limited to IGF1, FGF2, BMP2, BMP4 and BMP6. and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from stem cells is also provided wherein the media contains these factors. The use of cardiomyocytes and cardiac progenitors produced by the directed differentiation in transplantation and screening for cardiac compounds is also provided.Type: ApplicationFiled: December 22, 2006Publication date: August 13, 2009Applicant: ES CELL INTERNATIONAL PTE LTD,Inventors: Bruce Paul Davidson, Ralph Eberhard Graichen, Robert Zweigerdt, Xiuqin Xu, Christine Lindsay Mummery, William Sun
-
Publication number: 20090181007Abstract: A composition for in vitro use as a culture medium or in vivo use as a pharmaceutical composition or a medical device, capable of accelerating the differentiation of stem cells into cells with a chondrocytic phenotype and of restoring the original trophism of chondrocytes, is described. The composition comprises, in combination, at least one proteolytic enzyme, at least one growth factor and at least one from a sugar, an amino acid, a vitamin factor, a vitamin, a nucleotide and a nucleoside, in a physiologically acceptable carrier or diluent. A method of differentiating stem cells in cells having a chondrocytic phenotype, the cells obtained by the method and their uses, for example in human or animal cell therapy, for example by CBMP (Cellular Based Medicinal products) are also described.Type: ApplicationFiled: April 12, 2007Publication date: July 16, 2009Inventors: Luisa Gennero, Antonio Ponzetto, Enrico De Vivo, Luciano Contu, Emanuella Morra, Chiara Cesano, Giovanni Cavallo, Giuseppe Cicero, Gian Piero Pescarmona, Tetyana Denysenko, Maria Augusta Roos, Maurizio Sara
-
Publication number: 20090170200Abstract: A medium for culturing stem cell. The stem cell medium of the invention comprises a fetal bovine serum, one or plurality of amino acid, one or plurality of vitamin, one or plurality of growth factor, one or plurality of inorganic salt, one or plurality of antioxidant, wherein the stem cell medium has a calcium concentration of less than about 1.8 mM, and the fetal bovine serum is present in an amount of less than about 10% by volume of the medium. The stem cell medium of the invention can maintain the proliferative and self-renewal capacity of the stem cells and keep stem cells at a steady stage.Type: ApplicationFiled: April 21, 2008Publication date: July 2, 2009Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Ching-Hua Yeh, Gwo-Jaw Wang, Mei-Ling Ho, Je-Ken Chang, Chung-Hwan Chen
-
Publication number: 20090148420Abstract: Stem cells obtained through in vitro culture with heparan sulphate are described.Type: ApplicationFiled: August 8, 2008Publication date: June 11, 2009Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie COOL, Victor NURCOMBE
-
Publication number: 20090142316Abstract: The present invention relates to the use of dendrimers with monophosphonic or bisphosphonic terminations in order to stimulate the growth of cell cultures or to activate cells in culture.Type: ApplicationFiled: July 29, 2005Publication date: June 4, 2009Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M, RHODIA UK LIMITEDInventors: Jean-Pierre Majoral, Anne-Marie Jeannine Jacqueline Caminade, Jean-Jacques Fournie, Laurent Griffe, Mary Poupot-Marsan, Remy Poupot, Cedric-Olivier Turrin
-
Patent number: 7541188Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to improved methods for organotypic culture of skin substitutes. In some embodiments, the dermal equivalent of the skin substitute is lifted to air interface of the culture prior to seeding with keratinocytes. In other embodiments, increased concentrations of collagen are used to form the dermal equivalent. In still other embodiments, optimized media are utilized to maintain the skin equivalents.Type: GrantFiled: December 7, 2004Date of Patent: June 2, 2009Assignee: Stratatech CorporationInventors: Paul Barth Conrad, Cathy Ann-Rusmussen Ivarie, Lynn Allen-Hoffmann
-
Patent number: 7537885Abstract: The present invention is directed to methods of preserving mammalian heart, ex vivo. Nanoparticle compositions for carrying out the invention are also disclosed.Type: GrantFiled: March 22, 2007Date of Patent: May 26, 2009Assignee: Lifeblood Medical Inc.Inventors: Joseph Fischer, Jan Baker, Robert G. L. Shorr
-
Publication number: 20090123503Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.Type: ApplicationFiled: January 6, 2009Publication date: May 14, 2009Applicant: SkinMedica. Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Publication number: 20090098650Abstract: The present invention describes novel compositions for deriving, maintaining and growing pluripotent and germ-line competent mammalian embryonic stem cells. The compositions of this invention refer to compositions comprising a 1) conditioned medium of a cell line expressing limited amounts of Leukemia Inhibitory Factor (LIF), 2) conditioned medium from a cell line transfected with mammalian LIF and 3) a medium supplemented with recombinant rabbit LIF. The present invention describes novel compositions for deriving, maintaining and growing adult human stem cells and/or adult early progenitor cells, preferably under stroma-free conditions and without added LIF and/or cytokines or growth factors. The media of the present invention are used for the generation of pluripotent and germ-line competent embryonic stem cells of mammals of which these cells were not obtained up to now. The media of the present invention are used for the generation of adult human stem cells and/or adult early progenitor cells.Type: ApplicationFiled: November 20, 2008Publication date: April 16, 2009Applicant: Thromb-X n.v.Inventor: Luc SCHOONJANS
-
Patent number: 7514261Abstract: The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging.Type: GrantFiled: August 8, 2002Date of Patent: April 7, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Jay M. Edelberg, Shahin Rafii, Mun K. Hong
-
Publication number: 20090035346Abstract: Disclosed is an implantable material comprising a biocompatible matrix and cells which, when provided to a vascular access structure, can promote functionality generally. For example, implantable material of the present invention can enhance maturation of an arteriovenous native fistula as well as prolong the fistula in a mature, functional state suitable for dialysis. Additionally, the present invention can promote formation of a functional arteriovenous graft suitable for dialysis as well as promote formation of a functional peripheral bypass graft. Implantable material can be configured as a flexible planar form or a flowable composition with shape-retaining properties suitable for implantation at, adjacent or in the vicinity of an anastomoses or arteriovenous graft. According to the methods disclosed herein, the implantable material is provided to an exterior surface of a blood vessel. Certain embodiments of the flexible planar form define a slot.Type: ApplicationFiled: June 5, 2006Publication date: February 5, 2009Applicant: Pervasis Therpeutics, Inc.Inventors: Helen Marie Nugent, Elazer Edelman, Anupam Dalal, Steve Bollinger, Scott Epperly
-
Publication number: 20090035860Abstract: The invention provides media formulations. A complete media formulation of the invention includes, for example, the following components: albumin, an iron carrier, glutamine, a glycosidase or hydrolase, fibroblast growth factor (FGF), a salt or mineral, and essential amino acids, at an osmolarity of about 220-330 mOsm/Liter.Type: ApplicationFiled: January 3, 2008Publication date: February 5, 2009Applicant: CALIFORNIA STEM CELL, INC.Inventor: GABRIEL NISTOR
-
Patent number: 7485460Abstract: The present invention encompasses methods and compositions for enhancing the growth of adult marrow stromal cells.Type: GrantFiled: May 21, 2003Date of Patent: February 3, 2009Assignee: Tulane University Health Sciences CenterInventors: Darwin Prockop, Ichiro Sekiya, Carl Gregory, Jeffrey Spees, Jason Smith, Radhika Pochampally
-
Publication number: 20090029464Abstract: Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if an antagonist of bone morphogenic protein is added to the medium in which the stem cells are cultured, together with fibroblast growth factor, the stem cells will remain undifferentiated indefinitely, even without feeder cells or conditioned medium.Type: ApplicationFiled: September 29, 2008Publication date: January 29, 2009Inventors: Ren-He Xu, James A. Thomson
-
Patent number: 7452726Abstract: The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and/or detection of particles, such as cells and/or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and/or analysis of particles, such as cells, viruses, organelles, beads, and/or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement/positioning, retention/localization, treatment, measurement, release, and/or output of particles. Furthermore, these mechanisms may be combined in any suitable order and/or employed for any suitable number of times within a system.Type: GrantFiled: December 11, 2003Date of Patent: November 18, 2008Assignee: Fluidigm CorporationInventors: Hou-Pu Chou, Antoine Daridon, Kevin Farrell, Brian Fowler, Yish-Hann Liau, Ian D. Manger, Hany Ramez Nassef, William Throndset